Diagnostic utility of HPV-16/18 E6 mRNA fold change measured by in-house semi-quantitative real-time PCR in cervical cancer triage for differentiation of CIN3 and cervical cancer from lower-grade lesions.
A rapid HPV test measuring E6 mRNA could help identify cervical precancers in resource-limited settings with high sensitivity and specificity.
Cervical cancer remains a major public health concern in low- and middle-income countries, where screening and triage resources are limited. An E6 FC cutoff of ≥0.648 yielded 95.24% sensitivity and 86.36% specificity.
What the study was
- Study design
- Assay development and validation study
- Population
- Women with HPV-positive cervical samples in low- and middle-income country setting
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Diagnostic microbiology and infectious disease
Why it surfaced
Novel low-cost HPV mRNA triage assay for cervical cancer screening in LMICs; distinguishes transforming from transient HPV infections; directly EARLY_CANCER_DETECTION watchlist; high unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.